PIK3R1 and invasive breast carcinoma: For example, TP53 nonsynonymous mutations were associated with increased T cell infiltrate in breast invasive carcinoma estrogen receptor-positive (BRCA ER+) tumors (estimate = 2.56, adjusted P = 6 × 10−4), while PIK3R1 nonsynonymous mutations were associated with T cell-enriched glioblastomas (estimate = 7.23, adjusted P = 0.003).